Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Early real-world experience with revumenib outside of a clinical trial setting: A single center retrospective review of efficacy and tolerability

View Full Paper
Ask AI
Bookmark
Share

Authors

UIUmar IqbalAWAlison WalkerAKAndrew Kuykendall

Discussion

Loading...

Member takes

Overview

Retrospective review shows 79% overall response rate for revumenib in acute leukemias, highlighting early efficacy and tolerability data.

Key Points

  • Early real-world data shows 79% overall response rate for revumenib, indicating strong efficacy.
  • 14 of 16 efficacy-evaluable patients treated achieved complete remission or better, confirming tolerability.
  • Retrospective review of institutional data including patients treated with both hypomethylating agents and revumenib.
  • Highlights the need for further research into the long-term effects and efficacy across molecular subsets.

Cite This Study

Iqbal et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d3a9https://doi.org/10.1182/blood-2025-3448
View Full Paper
Ask AI
Bookmark
Share